(Total Views: 421)
Posted On: 09/18/2021 6:54:11 AM
Post# of 72451
All eyes here:
https://clinicaltrials.gov/ct2/show/NCT04784897
This link will show you the updated phase 2 info.
For example: ClinicalTrials.gov Identifier: NCT04784897
Recruitment Status : Completed
First Posted : March 5, 2021
Last Update Posted : August 13, 2021
Note the actual PR date.
WAKEFIELD, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provided additional information regarding the status of its randomized, double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for the treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897). The Company is developing Brilacidin for treatment of COVID-19 under U.S. FDA Fast Track designation.
Mr Ehrlech favored us by releasing the PR first before the recording.
Bravo Mr Ehrlech and thank you.
So note well as the PR comes out I’m going to guess you can pair it up to the report the next day. God businesses practice vetting critical data.
I believe Mr Ehrlech will honor us with a truthful and professional high quality PR. Enhanced with facts and direction which will be spiced with clue for the astute.. smiley face.
https://clinicaltrials.gov/ct2/show/NCT04784897
This link will show you the updated phase 2 info.
For example: ClinicalTrials.gov Identifier: NCT04784897
Recruitment Status : Completed
First Posted : March 5, 2021
Last Update Posted : August 13, 2021
Note the actual PR date.
WAKEFIELD, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provided additional information regarding the status of its randomized, double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for the treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897). The Company is developing Brilacidin for treatment of COVID-19 under U.S. FDA Fast Track designation.
Mr Ehrlech favored us by releasing the PR first before the recording.
Bravo Mr Ehrlech and thank you.
So note well as the PR comes out I’m going to guess you can pair it up to the report the next day. God businesses practice vetting critical data.
I believe Mr Ehrlech will honor us with a truthful and professional high quality PR. Enhanced with facts and direction which will be spiced with clue for the astute.. smiley face.
(3)
(1)
Ronald A Phillips
